



Corporate headquarters:  
Crown Bioscience Inc.  
3375 Scott Blvd., Suite 108  
Santa Clara, CA 95054  
Tel: 855.827.6968 - Fax: 888.882.4881

[www.crownbio.com](http://www.crownbio.com)  
[busdev@crowbio.com](mailto:busdev@crowbio.com)

Clarity With  
**CrownBio**  
Recognize Your Next Clinical Candidate When You See It

# Translational Oncology and the Impact of Immuno-Oncology

...a global challenge that requires a personal touch



## Hilton La Jolla @ Torrey Pines

10950 N Torrey Pines Rd, La Jolla, CA 92037

Thursday September 15th, 2016

Crown Bioscience welcomes you to our second San Diego symposium on Translational Oncology and the impact of the rapidly growing area of Immuno-Oncology agents in Drug Discovery and the clinic.

This symposium is exclusively for Oncology R&D and Clinical teams from industry and medical research. The objective is simple – to foster a greater understanding of the Translational Technologies in use today across research and clinical communities empowering users to deliver improvements in both the development of drugs before they enter clinical trials and as an adjunct to clinical trials to support decision-making.

CrownBio has seen tremendous changes in the acceptance of key translational tools such as PDX to improve the development of targeted therapies and as a way to investigate efficacy across a broad spectrum of patient populations. As the delivery of Immuno-Oncology therapies continues to gain momentum, we would like to share our current knowledge with the drug discovery and clinical communities, and also sponsor a forum for scientists and clinicians to discuss the merits of current and future approaches as well as share experiences.

The event will be free to attend for all invited guests, and lunch will be provided. There are a limited number of places, so please register early. Simply send an email to [busdev@crowbio.com](mailto:busdev@crowbio.com) with your request to join the event. If we have to limit the number of invitations, any requests we cannot accept will be offered a priority place for the next Symposium. The agenda for the day is on the next page.

*We look forward to welcoming you to this unique opportunity to hear about the latest research from experts in our field. How the Oncology community is translating the promise of Immunotherapy from the laboratory to the clinic and the impact of combination therapy to provide improved intervention for patients.*

**Dr Jean-Pierre Wery, CEO, Crown Bioscience Inc.**





# Translational Oncology and the Impact of Immuno-Oncology

...a global challenge that requires a personal touch

08:30

**Registration and coffee**

09:00

**Welcome and Opening Remarks**

Dr Guo-Liang Yu, Executive Chairman, Crown Bioscience Inc.

09:10

**The Chairman's Introduction and Opening Remarks**

Dr Rob Kramer, Consultant (previously VP and Global Head Oncology Discovery, J&J)

09:15

**Positioning Oncology Drug Discovery for Phase 1 Success:** Dr John Boylan, Executive Director, Integrative Research and Development, Celgene

09:45

**ARRY-382, a Potent and Highly-Specific CSF1R Immunokinase Inhibitor: Potential Therapeutic Utility in Combination with Immune Checkpoint Inhibitors:** Dr Patrice Lee, VP at Array BioPharma

10:15

**Break**

10:30

**Virtual R&D with a Multiple Toll-Like Receptor Agonist for Cancer Immunotherapy:** Dr Micheal Newman, President and CEO Decoy Biosystems, Inc.

11:00

**Panel Discussion: Case Study HuTrial™** (Dr Elisabeth Gardiner, CSO, Meditope Biosciences, Inc., Dr Tommy Broudy, General Manager, Crown Bioscience SD, Dr Henry Li, VP of Translational Oncology, Crown Bioscience Inc. and Dr Ken Lloyd, Chief Scientific Officer, BeyondSpring Pharmaceuticals)

12:00

**Lunch & networking**

13:00

**PDX Trials Using Humanized NSG Mice: A Translational Platform for Immuno-oncology Therapeutic Development:** Dr Tommy Broudy, General Manager, Crown Bioscience San Diego

13:30

**Perspectives on Drug Discovery and Development:** Dr Neil Gibson, Senior VP, BioAtla

14:00

**Inhibition of Class I HDACs as an Epigenetic Priming Strategy to Circumvent Immune Checkpoint Inhibitor Resistance:** Dr Jamie Christensen, Chief Scientific Officer at Mirati Therapeutics

14:30

**Immuno-Oncology: Where do we go from here?** Dr Rob Kramer, Consultant (previously VP and Global Head Oncology Discovery, J&J)

15:00

**Break**

15:15

**Panel Discussion: Case Study MuScreen™** (Dr Leslie Sharp, Director Immuno-Oncology, BioAtla, Dr Alan Wahl, Principal – Westwahl LLC, and Dr Eric Murphy, Global Head Oncology R&D and External Innovations, Crown Bioscience Inc.)

16:15

**The Chairman's Closing Remarks & Networking**

Dr Rob Kramer, Consultant (previously VP and Global Head Oncology Discovery, J&J)





Corporate headquarters:  
 Crown Bioscience Inc.  
 3375 Scott Blvd., Suite 108  
 Santa Clara, CA 95054  
 Tel: 855.827.6968 - Fax: 888.882.4881

www.crownbio.com  
 busdev@crownbio.com

# Clarity With CrownBio

Recognize Your Next Clinical Candidate When You See It



# Translational Oncology and the Impact of Immuno-Oncology

...a global challenge that requires a personal touch

## Hilton La Jolla @ Torrey Pines

10950 N Torrey Pines Rd, La Jolla, CA 92037

Thursday September 15th, 2016

## How to get there...

From I5 take Junction 29 onto Genesee Avenue in the direction of Torrey Pines. After about 1.2 miles, the road becomes N Torrey Pines Road, and the Hilton La Jolla is the exit on your left hand side.

